LPL Financial’s Cardiol Therapeutics CRDL Stock Holding History

LPL Financial’s Portfolio CRDL Stock Details CRDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-15,210	Closed	-$20.7K	–	5842
2025 Q2	$20.7K	Buy	+15,210	New	+$17.7K	﹤0.01%	5470
2025 Q1	–	Sell	-18,310	Closed	-$23.4K	–	5388
2024 Q4	$23.4K	Buy	18,310 +5,000	+38%	+$8.43K	﹤0.01%	5180
2024 Q3	$26.4K	Buy	+13,310	New	+$27.6K	﹤0.01%	5061
2022 Q3	–	Sell	-10,230	Closed	-$14K	–	4435
2022 Q2	$14K	Buy	+10,230	New	+$14.6K	﹤0.01%	4369

Other funds holding CRDL

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

LPL Financial's CRDL Position: Q3 2025 in Review

LPL Financial sold out of Cardiol Therapeutics (CRDL) in Q3 2025, closing a stake of 15,210 shares — an estimated $20.7K sold.

LPL Financial first reported a position in CRDL in Q2 2022 and held it in 4 quarters. The position peaked at $26.4K in Q3 2024. 48 funds tracked by Wall St. Rank hold CRDL as of Q3 2025.

LPL Financial reported no remaining Cardiol Therapeutics position as of Q3 2025 after selling out during the quarter.
LPL Financial sold 15,210 Cardiol Therapeutics shares in Q3 2025, an estimated $20.7K.
LPL Financial first reported a position in Cardiol Therapeutics in Q2 2022 and held it in 4 quarters.
LPL Financial's Cardiol Therapeutics position peaked at $26.4K in Q3 2024.
48 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q3 2025.

Based on LPL Financial's 13F filing for Q3 2025, filed 12 Nov 2025.